Genentech and Novartis have been swept into a newly unsealed whistleblower lawsuit that accuses several drugmakers of running a decades-long kickback scheme to pump up prescriptions of the allergy biologic Xolair across dozens of states. The complaint, originally filed under seal earlier this year, was opened to public view on Thursday and alleges that the companies routed improper payments through specialty pharmacies and patient assistance programs, leading to false Medicare and Medicaid claims. The relators, acting through Pharma Integrity LLC, are seeking trebled damages and civil penalties on behalf of 30 states and Washington, D.C.
What the complaint says was happening
According to Fierce Pharma, the 143-page filing alleges that Novartis, Genentech and other manufacturers showered specialty pharmacies, including Walgreens, Express Scripts and CVS, with perks such as office equipment, expensive dinners and sports-event outings. In return, the pharmacies allegedly provided falsified coding and paperwork that sped reimbursement for Xolair. The lawsuit also claims the companies used disease-specific co-pay charities as kick-back pass-throughs to expand market share and to funnel false coverage instructions to government payors. The relators say those tactics triggered “hundreds of millions, if not billions” of dollars in false claims to Medicare and state Medicaid programs.
How the case came into view
Public docket entries show the complaint was filed under seal on January 20, and that U.S. District Court Judge Michelle Williams lifted the seal on Thursday, giving the relator until July 20 to formally serve the defendants. Records on PACER Monitor indicate that Maryland and Florida have declined to intervene, while the other named states are not intervening at this time. Coverage from Bloomberg Law and other outlets has tracked the Central District of California docket as the case moved toward unsealing.
Scale and stakes
Xolair is not a bit player on anyone’s balance sheet. Financial filings from Novartis list roughly $1.72 billion in net Xolair sales for 2025, reflecting the drug’s expansion into additional allergy indications. Genentech’s parent company Roche has flagged Xolair as one of its top growth drivers in investor materials. And as Fierce Pharma notes, Roche reported around $3.7 billion (3.08 billion Swiss francs) in U.S.-specific Xolair sales, a haul that helps explain why the relators are seeking triple damages and stiff penalties.
Local impact in South San Francisco
Genentech, headquartered in South San Francisco, is one of the Bay Area’s biggest biotech employers, so any case that touches its flagship products is bound to get attention close to home. The company runs a large campus at 1 DNA Way in South San Francisco, and Genentech lists operational contact information for the site online.
Legal framework and potential penalties
The lawsuit is filed under the federal False Claims Act, which lets private parties, known as relators, sue on the government’s behalf and seek triple damages along with civil penalties for each false claim. The Department of Justice explains that these qui tam cases are filed under seal while federal authorities decide whether to intervene, and that recoveries can include treble damages plus significant per-claim fines. If a court ultimately finds systemic billing misconduct, that structure can turn questionable reimbursement practices into extremely expensive problems.
What happens next
With the seal lifted, the clock is officially ticking. The relator has until July 20 to serve the complaint, and the states or the Department of Justice could still choose to intervene in all or part of the case. Docket entries on PACER Monitor and reporting from Bloomberg Law suggest the litigation could stretch on for months or years, given the number of defendants and the breadth of the alleged conduct. In the meantime, regulators and prosecutors will weigh whether the government’s interests justify stepping in and pursuing a deeper investigation.
